Evidence map›Paper›PMID 40822349›Full record

ArticleiScience2025

Triclabendazole suppresses cellular levels of glycosaminoglycan-A potential therapeutic agent for mucopolysaccharidoses and related diseases.

Seigo Terawaki, Filipp Vasilev, Viktoriia Sofronova, Misa Tanaka, Yoshiko Mori, Rina Iwata, Takahito Moriwaki, Toshiharu Fujita, Nadezhda Maksimova, Takanobu Otomo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Seigo TerawakiDepartment of Molecular and Genetic Medicine, Kawasaki Medical School, Kurashiki 701-0192, Japan.
Filipp VasilevDepartment of Molecular and Genetic Medicine, Kawasaki Medical School, Kurashiki 701-0192, Japan.
Viktoriia SofronovaDepartment of Molecular and Genetic Medicine, Kawasaki Medical School, Kurashiki 701-0192, Japan.
Misa TanakaDepartment of Clinical Genomics, Saitama Medical University, Saitama 350-0495, Japan.
Yoshiko MoriDepartment of Molecular and Genetic Medicine, Kawasaki Medical School, Kurashiki 701-0192, Japan.
Rina IwataDepartment of Molecular and Genetic Medicine, Kawasaki Medical School, Kurashiki 701-0192, Japan.
Takahito MoriwakiDepartment of Molecular and Genetic Medicine, Kawasaki Medical School, Kurashiki 701-0192, Japan.
Toshiharu FujitaDepartment of Molecular and Genetic Medicine, Kawasaki Medical School, Kurashiki 701-0192, Japan.
Nadezhda MaksimovaLaboratory of Molecular Medicine and Human Genetics, North-Eastern Federal University, Yakutsk, Sakha Republic 677013, Russia.
Takanobu OtomoDepartment of Molecular and Genetic Medicine, Kawasaki Medical School, Kurashiki 701-0192, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mucopolysaccharidosis-plus syndrome (MPSPS) is an autosomal recessive inherited disorder of mucopolysaccharide metabolism with a severe clinical course. The causative gene

Indexed as

Biological sciencesClinical geneticsHealth sciencesMedical specialtyMedicineNatural sciencesPathophysiologyPhysiology

Identifiers

PMID40822349
PMCPMC12355420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.